bioRxivMicrobiology
Human gut Actinobacteria boost drug absorption by secreting P-glycoprotein ATPase inhibitors
T. S. Kyaw, M. Sandy, K. Trepka, J. Goh, K. Yu, V. Dimassa, E. Bess, J. Bisanz, P. J. Turnbaugh
Abstract
Drug efflux transporters are a major determinant of drug efficacy and toxicity. A canonical example is P-glycoprotein (P-gp), an efflux transporter that controls the intestinal absorption of diverse compounds. Despite reports that P-gp expression depends on the microbiome, the mechanisms responsible and their physiological relevance remain unclear. Surprisingly, we found that the cardiac drug-metabolizing gut Actinobacterium Eggerthella lenta increases drug absorption in mice through post-translational inhibition of P-gp ATPase efflux activity. P-gp inhibition is conserved in the Eggerthellaceae family but absent in other Actinobacteria. Comparative genomics identified genes associated with P-gp inhibition. Finally, activity-guided biochemical fractionation coupled to metabolomics identified a cluster of isoflavonoids produced by E. lenta related to plant-derived P-gp inhibitors. These results highlight the unexpected overlap between diet- and microbiome-derived compounds, and the importance of considering the broader relevance of the gut microbiome for drug disposition beyond first-pass metabolism. One Sentence SummaryThe gut bacterium Eggerthella lenta secretes inhibitors of P-glycoprotein ATPase activity, accelerating drug absorption.
- organism: mouse
- assay: metabolomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Influence of Gut Microbiota on Oral Drug Absorption and Metabolism
Douglas A. Nelson, Vaishnavi Veerareddy, … Karunya K. Kandimalla·bioRxiv·Feb 16, 2025
- Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives
L. Zou, P. Spanogiannopoulos, … P. J. Turnbaugh·bioRxiv·Oct 28, 2019
- Gut bacteria generate prodrugs in situ increasing systemic drug exposure
Ting-Hao Kuo, Anoop Singh, … Michael Zimmermann·bioRxiv·Dec 9, 2025
- Establishing an in vitro pipeline for the high-throughput quantification of epithelial permeability of gut bacterial metabolites
Amber Brauer-Nikonow, Carlos Geert Pieter Voogdt, … Michael Zimmermann·bioRxiv·Jun 10, 2025
- Microbiota-induced active translocation of peptidoglycan across the intestinal barrier dictates its within-host dissemination
R. Wheeler, P. A. D. Bastos, … I. G. Boneca·bioRxiv·Apr 20, 2022
- Novel inhibitors of E. coli lipoprotein diacylglyceryl transferase are insensitive to resistance caused by lpp deletion
J. Diao, R. Komura, … S. B. Kapadia·bioRxiv·Oct 4, 2020